Steven J Isakoff
Overview
Explore the profile of Steven J Isakoff including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
108
Citations
8197
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Bar Y, Fell G, Dedeoglu A, Moffett N, Vidula N, Spring L, et al.
NPJ Breast Cancer
. 2025 Mar;
11(1):27.
PMID: 40069204
Trastuzumab deruxtecan (T-DXd) is approved for HER2-low (HER2 immunohistochemistry (IHC)1+ or 2+ with non-amplified in situ hybridization (ISH)), but not HER2-0 (IHC 0) metastatic breast cancer. The impact of repeat...
2.
Spring L, Scarpetti L, Medford A, Niemierko A, Comander A, Mulvey T, et al.
NPJ Breast Cancer
. 2025 Jan;
11(1):2.
PMID: 39774684
Optimal timing and dosing of adjuvant cyclin-dependent kinase (CDK) 4/6 inhibitor in early breast cancer is controversial. This prospective phase II clinical trial investigated tolerability and safety of two ribociclib...
3.
Abelman R, Wu B, Barnes H, Medford A, Norden B, Putur A, et al.
Clin Cancer Res
. 2025 Jan;
PMID: 39745368
Purpose: Antibody-drug conjugates (ADCs) harboring topoisomerase I (TOP1) inhibitor payloads have improved survival for patients with metastatic breast cancer (MBC). However, knowledge of ADC resistance mechanisms and potential impact on...
4.
Wu B, Thant W, Bitman E, Liu T, Liu J, Paschalis E, et al.
bioRxiv
. 2024 Dec;
PMID: 39677819
Immune exclusion inhibits anti-tumor immunity and response to immunotherapy, but its mechanisms remain poorly defined. Here, we demonstrate that Trophoblast Cell-Surface Antigen 2 (TROP2), a key target of emerging anti-cancer...
5.
Dent R, Kim S, Oliveira M, Barrios C, OShaughnessy J, Isakoff S, et al.
Clin Cancer Res
. 2024 Jul;
30(19):4329-4338.
PMID: 39058425
Purpose: In the randomized phase II LOTUS trial, combining ipatasertib with first-line paclitaxel for triple-negative breast cancer (TNBC) improved progression-free survival (PFS), particularly in patients with PIK3CA/AKT1/PTEN-altered tumors. We aimed...
6.
Tarantino P, Tayob N, Villacampa G, Dang C, Yardley D, Isakoff S, et al.
J Clin Oncol
. 2024 Jun;
42(31):3652-3665.
PMID: 38935923
Purpose: Long-term outcomes of patients with stage I human epidermal growth factor receptor 2 (HER2)-positive breast cancer receiving adjuvant trastuzumab emtansine (T-DM1) remain undefined, and prognostic predictors represent an unmet...
7.
Deng B, Muldoon A, Cormier J, Mercaldo N, Niehoff E, Moffett N, et al.
J Biomed Opt
. 2024 May;
29(6):066001.
PMID: 38737790
Significance: Achieving pathologic complete response (pCR) after neoadjuvant chemotherapy (NACT) is a significant predictor of increased likelihood of survival in breast cancer patients. Early prediction of pCR is of high...
8.
Bardia A, Sun S, Thimmiah N, Coates J, Wu B, Abelman R, et al.
Clin Cancer Res
. 2024 May;
30(14):2917-2924.
PMID: 38709212
Purpose: The antibody-drug conjugate (ADC) sacituzumab govitecan (SG) comprises the topoisomerase 1 (TOP1) inhibitor (TOP1i) SN-38, coupled to a monoclonal antibody targeting trophoblast cell surface antigen 2 (TROP-2). Poly(ADP-ribose) polymerase...
9.
Bar Y, Keenan J, Niemierko A, Medford A, Isakoff S, Ellisen L, et al.
NPJ Breast Cancer
. 2024 Apr;
10(1):27.
PMID: 38605020
We aimed to study the incidence and genomic spectrum of actionable alterations (AA) detected in serial cfDNA collections from patients with metastatic breast cancer (MBC). Patients with MBC who underwent...
10.
Gao L, Medford A, Spring L, Bar Y, Hu B, Jimenez R, et al.
Breast Cancer Res Treat
. 2024 Feb;
205(2):211-226.
PMID: 38355821
Background: This paper is a narrative review of a major clinical challenge at the heart of breast cancer care: determining which patients are at risk of recurrence, which require systemic...